Xuezhikang Capsule for Type 2 Diabetes with Hyperlipemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trails

Abstract EN

Objective.

To evaluate the efficacy and safety of Xuezhikang capsule treating type 2 diabetes with hyperlipidemia.

Methods.

We searched six databases to identify relevant studies published before January 2015.

Two review authors independently extracted data and assessed the Cochrane risk of bias tool.

We resolved disagreements with this assessment through discussion and a decision was achieved by consensus.

Results.

We included 21 studies (1548 participants).

Treatment courses were at least 8 weeks.

Overall, the risk of bias of included trials was unclear.

Among them, 16 studies could conduct meta-analysis.

The result showed that compared with routine group (5 studies), Xuezhikang group had more effect on decreasing TC, TG, LDL-C, and rising HDL-C.

However, compared with statins group (11 studies), Xuezhikang group has less effect on decreasing TC, TG, and rising HDL-C.

Meanwhile, two groups had no statistical differences of LDL-C level.

Conclusion.

Xuezhikang capsule may be effective for treating type 2 diabetes with hyperlipemia.

Our findings should be considered cautiously due to unclear risk of bias of the included studies and low methodological quality.

Therefore, more strictly designed large-scale randomized clinical trials are needed to evaluate the efficacy of Xuezhikang capsule in type 2 diabetes with hyperlipemia.